FDA re­quires Re­gen­eron, Lil­ly to mon­i­tor vari­ants as a con­di­tion of mAb EUAs

As part of an ef­fort to shore up pub­lic con­fi­dence in the FDA’s emer­gency use au­tho­riza­tion process­es, the agency on Mon­day re­leased ad­di­tion­al sci­en­tif­ic re­view …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER